Kaplan–Meier analysis suggested that APOBEC3B has no directive relationship with the OS of AML patients, whereas the APOBEC3G overexpression presented significantly shorter OS, and the ROC analysis showed APOBEC3G had a larger AUC of survival time than APOBEC3B for a 3-year prediction, which indicated that high APOBEC3G expression can be an unfavorable indicator for AML OS prediction. The gene discussed is APOBEC3B; the disease is acute myeloid leukemia.